Novo Nordisk A/s

Novo Nordis A/s

Erik B Nielsen

Erling Guddal

Rolf Hohlweg

Peter Faarup

Louis B Hansen

Kristian Tage Hansen

Peter H Andersen

Frederik Gronwald

Birgitte Hjort Guldhammer

Christian Foged

Rolf Holweg

Birte Kloppenborg Skrumsager

A method of inhibiting one or more psychiatric disorders is disclosed comprising administering a compound of formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C.sub.1-6, alkyl, C.sub.1-6 alkoxy or (tertiary amino)C.sub.1-6 alkoxy; and R.sup.2 and R.sup.3 are individually hydrogen or C.sub.1-6 alkyl, or a pharmaceutically acceptable salt thereof.

3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders

Tricyclic benzazepines having the general formula ##STR1## wherein A together with the .alpha.- and .beta.-marked carbon atoms is a cyclopentene, cyclohexene, furan, dihydrofuran, pyran, dihydropyran, thiophene, oxazole, pyrrole, pyrroline, tetrahydropyridine or dioxole ring, R.sup.1 is H or alkyl, R.sup.2 and R.sup.3 independently are H, alkoxy, halogen, nitro, cyano or hydroxy, or R.sup.2 and R.sup.3 together may form a furan, dihydrofuran, cyclopentene or dioxole ring and R.sup.4 is H, alkoxy, nitro, cyano, hydroxy or halogen, or a pharmaceutically acceptable salt thereof, are useful in treatment of certain disorders in the central nervous system, e.g., psychosis, pain, depression, sleep disturbances, dyskinesia, Parkinson's disease, stroke.

Tricyclic 2,3,4,5-tetrahydro-1H-3-benzapines

2,3,4,5-Tetrahydro-1H-3-benzazepines having the general formula ##STR1## wherein R.sup.1 is Cl or Br; R.sup.3 and R.sup.4 are hydrogen, halogen, CF.sup.3, CN, NO.sub.2, or NH.sub.2. The compounds are useful in treatment of certain disorders in the central nervous system.

2,3,4,5-tetrahydro-1H-3-benzazepines

A disubstituted piperazine compound having the formula ##STR1## wherein R.sup.1 is halogen, methoxy, C.sub.1-6 -alkyl or trifluoromethyl, and R.sup.2 is methyl or substituted C.sub.1-8 -alkyl, C.sub.3-8 -alkenyl or C.sub.3-8 -cycloalkyl, where substituents may be hydroxy-, keto- or oximino-groups in any position leading to a stable tertiary amine; or R.sup.2 is a straight or branched C.sub.1-8 -alkyl or C.sub.3-8 -alkenyl, which in any position may be substituted as above, but is terminally substituted with one of the following groups: cyano, optionally C.sub.1-4 -alkoxy-substituted C.sub.1-4 -alkoxy, dimethoxy, optiontionally substituted phenoxy, phosphonic acid, thienyl, furyl, oxazoline, isoxazole, oxadiazole, where the optional substitution is represented by C.sub.1-6 -alkyl or phenyl, provided that when cyano is the only substituent in R.sup.2, R.sup.2 must contain at least four carbon atoms, and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of mental disorders in which a dopaminergic deficit is implicated.

1,4-disubstituted piperazines

A disubstituted piperazine compound having the formula I ##STR1## wherein R.sup.1 is thienyl or phenyl, which may be substituted with C.sub.1-6 -alkyl or halogen, and R.sup.2 is thienyl, which may be substituted with C.sub.1-6 -alkyl or halogen, and R.sup.3 is C.sub.1-8 -alkyl, C.sub.3-8 -alkenyl or C.sub.3-8 -cycloalkyl which all may be substituted with hydroxy, oximino or keto in any position giving a stable tertiary amine or R.sup.3 is C.sub.1-8 -alkyl or C.sub.3-8 -alkenyl which in any position may be substituted as above, but is terminally substituted with phenoxy, phenyl, thienyl, furyl, methoxy or --CN and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of mental disorders in which a dopaminergic deficit is implicated.

Novel 2,3,4,5-tetrahydro-1H-3-benzazepines having the formula ##STR1## wherein R.sup.3 represents H, C.sub.1-3 -alkyl or C.sub.3-7 -cycloalkyl;

Novel benzazepine derivatives

Novel 2,3,4,5-tetrahydro-1H-3-benzazepines having the formula ##STR1## wherein R.sup.3 represents H, C.sub.1-3 -alkyl or C.sub.3-7 -cycloalkyl; R.sup.4 represents hydrogen or R.sup.4 together with R.sup.10 represents a bridge which connects the positions to which R.sup.4 and R.sup.10 are linked, said bridge being --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --O--CH.sub.2 -- or --S--CH.sub.2 --;

Growing community of inventors

Vaerlose, Denmark

Erik B Nielsen